Kane Biotech Statistics

Total Valuation

Kane Biotech has a market cap or net worth of CAD 12.51 million. The enterprise value is 14.25 million.

Market Cap	12.51M
Enterprise Value	14.25M

Important Dates

The next estimated earnings date is Thursday, May 22, 2025.

Earnings Date	May 22, 2025
Ex-Dividend Date	n/a

Share Statistics

Kane Biotech has 166.77 million shares outstanding. The number of shares has increased by 4.72% in one year.

Current Share Class	166.77M
Shares Outstanding	166.77M
Shares Change (YoY)	+4.72%
Shares Change (QoQ)	-15.33%
Owned by Insiders (%)	39.62%
Owned by Institutions (%)	n/a
Float	100.70M

Valuation Ratios

The trailing PE ratio is 2.23.

PE Ratio	2.23
Forward PE	n/a
PS Ratio	6.21
PB Ratio	-18.16
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	2.55
EV / Sales	7.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.52

Financial Position

The company has a current ratio of 0.80

Current Ratio	0.80
Quick Ratio	0.48
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.41
Interest Coverage	-5.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-52.36%
Return on Invested Capital (ROIC)	-137.03%
Return on Capital Employed (ROCE)	-362.64%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.41
Inventory Turnover	1.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.43% in the last 52 weeks. The beta is 0.43, so Kane Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	-46.43%
50-Day Moving Average	0.09
200-Day Moving Average	0.11
Relative Strength Index (RSI)	34.09
Average Volume (20 Days)	48,983

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kane Biotech had revenue of CAD 2.01 million and earned 5.60 million in profits. Earnings per share was 0.04.

Revenue	2.01M
Gross Profit	993,602
Operating Income	-4.15M
Pretax Income	-4.91M
Net Income	5.60M
EBITDA	-4.15M
EBIT	-4.15M
Earnings Per Share (EPS)	0.04

Full Income Statement

Balance Sheet

The company has 544,377 in cash and 2.29 million in debt, giving a net cash position of -1.75 million or -0.01 per share.

Cash & Cash Equivalents	544,377
Total Debt	2.29M
Net Cash	-1.75M
Net Cash Per Share	-0.01
Equity (Book Value)	-688,646
Book Value Per Share	-0.01
Working Capital	-547,528

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.62 million and capital expenditures -26,652, giving a free cash flow of -5.65 million.

Operating Cash Flow	-5.62M
Capital Expenditures	-26,652
Free Cash Flow	-5.65M
FCF Per Share	-0.03

Full Cash Flow Statement

Margins

Gross margin is 49.36%, with operating and profit margins of -206.36% and 278.16%.

Gross Margin	49.36%
Operating Margin	-206.36%
Pretax Margin	-243.98%
Profit Margin	278.16%
EBITDA Margin	-206.42%
EBIT Margin	-206.36%
FCF Margin	n/a

Dividends & Yields

Kane Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.72%
Shareholder Yield	-4.72%
Earnings Yield	44.76%
FCF Yield	-45.15%

Stock Splits

The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.

Last Split Date	Mar 13, 2017
Split Type	Reverse
Split Ratio	0.2

Scores

Kane Biotech has an Altman Z-Score of -13.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.2
Piotroski F-Score	n/a